Victoria Johnson joined the MJH Life Sciences in 2020 and has written for NeurologyLive, CGTLive, and now HCPLive. You can reach her at vjohnson@mjhlifesciences.com
Lowering RA Disease Activity With Biologics Enhances Protective Cardiovascular PON1 Activity
Highest responders on DAS28 also had significantly greater decreases in 12-hydroxyeicosatetraenoic than low responders.
Read More
Review Finds Combination of Hands-on and Hands-off Treatment Improves Fibromyalgia Sleep Quality
Combining interventions yielded no significant differences in outcomes, pain, or quality-of-life.
Rurality Does Not Account for Disparities in Veteran Care for Rheumatoid Arthritis
Veterans residing in rural areas were only 10% more likely to initiate biologic therapies than those residing in rural areas.
Functional Exercise Training Reduced Pain in People With Fibromyalgia
The pain reduction effects did not last long beyond the scope of the trial, underscoring the importance of continuing such exercises.
SGLT-2 Inhibitors May be Beneficial in People With Kidney Stones and Gout
SGLT-2 inhibitors had more protective effects than GLP-1 receptor agonists or DPP-4 inhibitors in this population.
Autoimmune/Inflammatory Tissue Disorders Associated With COVID-19 Infection
A new cohort study including over 6 million participants has found an increased likelihood of Behçet disease, alocpecia, bulbous pemphigoid and other disorders post-COVID infection.
Whole-Body MRIs Reveal PsA Inflammation Improvements With Apremilast
The international phase 4 MOSAIC study is the first evaluating PsAMRIS and MRI-WIPE outcomes in patients with psoriatic arthritis.
Filgotinib Continues to Show Efficacy for RA in LTE Studies
Week 156 efficacy and safety data from the FINCH 4 study are consistent with that seen in FINCH 1, 2, and 3.
Nephrology Month in Review: October 2024
This nephrology month in review spotlights HCPLive’s coverage of ASN Kidney Week, the debut of a new podcast, and new research on IgA nephropathy.
FDA Accepts BLA for Denosumab Biosimilar
If approved, HLX14 would follow the first 2 denosumab biosimilar approvals in March 2024.
MASEF Score May Top FIB-4, Clinical Screening for Early MASH Detection
MASEF score seemed to be sensitive and effective in detecting at-risk MASH in 2 abstracts presented at the ACG 2024 Meeting.
HCV+ Organs Offer Better Waitlist, Survival Outcomes for Transplantation
Direct-acting antiviral agents have enabled more availability for organ transplant.
Apremilast Improves Outcomes in Scalp Psoriasis
The oral therapy may address limitations including difficulty in application and adverse events with topical therapies.
Roflumilast Reduces Disease Impact of Atopic Dermatitis
New PRO data from the INTEGUMENT-1 and –2 studies were presented at the ACAAI 2024 Meeting.
Rheumatology Month in Review: October 2024
The rheumatology month in review emphasizes new data on secukinumab, gout clinical decision making, and addressing sleep issues in fibromyalgia.
Biosimilars Month in Review: October 2024
The biosimilars month in review highlights new approvals, new safety findings, and new cost savings with biosimilars.
Semaglutide Reduces Knee Osteoarthritis Pain in People With Obesity
SF-36v2 scores also improved by 12 points with semaglutide compared with 6.5 points with placebo.
Podocyte Gene Therapy Seems Promising for IgAN in Preclinical Research
Mice models had improved disease phenotype and high transduction of PS-002 gene therapy.
Looking Deeper into Genetic Variants of FSGS, with Jennifer Lai Yee, MD, PhD, MPH
Yee discussed research she is conducting into gFSGS and nephrotic syndrome, presented at ASN Kidney Week.
Abdul Abdellatif, MD: More Gout Education Needed for Nephrologists
Abdellatif discussed the high prevalence of gout in patients with chronic kidney disease and the importance of screening and early treatment.
Ladan Zand, MD: Evaluating Obinutuzumab in Primary FSGS and Further Research
Zand discussed the unmet need for refractory primary FSGS and the importance of investigations specifically in this population.
Felzartamab Slows IgAN Decline in New Phase 2 Data
Complete, 24-month data from the IGNAZ study were presented at the ASN Kidney Week 2024 Meeting.
Abeona Completes Resubmission of Pz-cel Cell-Based Gene Therapy BLA for RDEB
The FDA originally issued a CRL requesting additional CMC data in April 2024.
Low-Dose CAR-T Shows Efficacy in Pediatric Systemic Lupus Erythematosus
Four of 5 participants with follow-up reaching 3 months have achieved SRI-4 disease responses.
Abdul Abdellatif, MD: Early Osteopenia Interventions Needed for Patients With Kidney Disease and Gout
Abdellatif discussed the importance of screening for osteopenia in patients with severe kidney disease.
Julie Refardt, MD, PhD: Current Hyponatremia Clinical Interventions Sufficient
Refardt discussed findings from the largest hyponatremia trial ever conducted, including 2174 participants across 9 European centers.
Dapagliflozin Lowers Risk of Decline in Late-Stage Kidney Disease
The dapagliflozin group had an average eGFR rate of -2.24 mL/min/1.73 m2 compared to -3.67 mL/min/1.73 m2 in the control group after about 1.5 years of follow-up.
Semaglutide Shows Benefit in CKD and Type 2 Diabetes Across Kidney Disease Severities
Participants receiving semaglutide had an overall hazard ratio of 0.76 in the composite primary outcome of kidney failure, serious eGFR decline, or death compared to placebo.
Will Herrington, MBBS, MD, MA: Empagliflozin Follow-up Data Informs Clinical Care for CKD
Herrington shared the carryover effects observed in the post-trial follow-up of the phase 3 EMPA-KIDNEY trial.
Jennifer Lai Yee, MD, PhD, MPH: Honing in on Sparsentan’s Benefit in Genetic FSGS
Yee discussed how the data show a benefit in this hard-to-treat population, similarly to the heterogeneous FSGS group.